BST:ETF

Stock Analysis Report

Executive Summary

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, manufacture, and licensing of proprietary orally administered controlled-release drug delivery systems and products.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Elite Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

ETF

-1.4%

DE Pharmaceuticals

1.7%

DE Market


1 Year Return

-29.4%

ETF

2.9%

DE Pharmaceuticals

7.2%

DE Market

Return vs Industry: ETF underperformed the German Pharmaceuticals industry which returned 2.9% over the past year.

Return vs Market: ETF underperformed the German Market which returned 7.2% over the past year.


Shareholder returns

ETFIndustryMarket
7 Day0%-1.4%1.7%
30 Day-42.1%-1.8%2.4%
90 Day58.4%8.8%2.3%
1 Year-29.4%-29.4%6.4%2.9%10.6%7.2%
3 Year-68.4%-68.4%32.6%17.7%18.4%8.1%
5 Year-79.7%-79.7%32.5%10.5%42.3%22.9%

Price Volatility Vs. Market

How volatile is Elite Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Elite Pharmaceuticals undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Elite Pharmaceuticals is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Elite Pharmaceuticals has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Elite Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Elite Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Elite Pharmaceuticals performed over the past 5 years?

29.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: ETF is unprofitable, but has reduced losses over the past 5 years at a rate of 29.3% per year.

Accelerating Growth: Unable to compare ETF's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ETF is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.9%).


Return on Equity

High ROE: ETF has a negative Return on Equity (-60.72%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: ETF is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: ETF is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Elite Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: ETF's short term assets ($8.5M) exceeds its short term liabilities ($7.6M)

Long Term Liabilities: ETF's short term assets (8.5M) exceeds its long term liabilities (4.6M)


Debt to Equity History and Analysis

Debt Level: ETF's debt to equity ratio (31.4%) is considered satisfactory

Reducing Debt: ETF had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet

Inventory Level: ETF has a high level of physical assets or inventory.

Debt Coverage by Assets: ETF's debt is covered by short term assets (assets are 2.258570x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ETF has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ETF has less than a year of cash runway if free cash flow continues to grow at historical rates of 10.2% each year.


Next Steps

Dividend

What is Elite Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage3.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate ETF's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ETF's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if ETF's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ETF's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ETF's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Elite Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

6.2yrs

Average management tenure


CEO

Nasrat Hakim (58yo)

6.2yrs

Tenure

US$1,048,000

Compensation

Mr. Nasrat Hakim has been the Chief Executive Officer and President of Elite Pharmaceuticals, Inc. since August 1, 2013. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience i ...


CEO Compensation Analysis

Compensation vs. Market: Nasrat's total compensation ($USD1.05M) is above average for companies of similar size in the German market ($USD209.32K).

Compensation vs Earnings: Nasrat's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

6.2yrs

Average Tenure

55yo

Average Age

Experienced Management: ETF's management team is seasoned and experienced (6.2 years average tenure).


Board Age and Tenure

6.9yrs

Average Tenure

67yo

Average Age

Experienced Board: ETF's board of directors are considered experienced (6.9 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Nasrat Hakim (58yo)

    Chairman

    • Tenure: 6.2yrs
    • Compensation: US$1.05m
  • Carter Ward (55yo)

    CFO, Secretary & Treasurer

    • Tenure: 10.3yrs
    • Compensation: US$192.82k
  • Doug Plassche (55yo)

    Executive Vice President of Operations

    • Tenure: 6.2yrs
    • Compensation: US$334.55k
  • Ken Smith

    Vice President of Legal

    • Tenure: 5yrs
    • Compensation: US$412.00k
  • Sophy Abraham

    Head of Regulatory Affairs

    • Tenure: 5yrs
  • Dianne Will

    Vice President of Investor Relations & Corporate Affairs

    • Tenure: 6.8yrs

Board Members

  • Jeffrey Whitnell (63yo)

    WardIndependent Director

    • Tenure: 10yrs
    • Compensation: US$30.00k
  • Barry Dash (88yo)

    Independent Director

    • Tenure: 14.5yrs
    • Compensation: US$30.00k
  • Nasrat Hakim (58yo)

    Chairman

    • Tenure: 6.2yrs
    • Compensation: US$1.05m
  • Davis Caskey (71yo)

    Independent Director

    • Tenure: 3.5yrs
    • Compensation: US$30.00k

Company Information

Elite Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Elite Pharmaceuticals, Inc.
  • Ticker: ETF
  • Exchange: BST
  • Founded: 1984
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$68.143m
  • Listing Market Cap: US$61.165m
  • Shares outstanding: 832.94m
  • Website: https://www.elitepharma.com

Number of Employees


Location

  • Elite Pharmaceuticals, Inc.
  • 165 Ludlow Avenue
  • Northvale
  • New Jersey
  • 7647
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ELTPOTCPK (Pink Sheets LLC)YesCommon StockUSUSDJul 1998
ETFBST (Boerse-Stuttgart)YesCommon StockDEEURJul 1998

Biography

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, manufacture, and licensing of proprietary orally administered controlled-release drug delivery systems ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/22 21:25
End of Day Share Price2019/10/22 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.